Skip to main content

Table 2 Information regarding patients’ infections and daptomycin usage

From: Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection 

Patients Surgical procedure Pathogen DAP Reason DAP dosage (mg/kg/day) DAP duration (days) Total parental antibiotics (days) Total time under DAP (%) Adverse effects Outcome Follow-up (months)
1 two-stage reimplantation MRSA intolerance 10 10 13 77 none success 26
2 two-stage reimplantation MRSA intolerance 8.3 18 35 51 none success 27
3 two-stage reimplantation MRCoNS CKD stage 5 3.3 12 15 80 none success 25
4 DAIR MRCoNS intolerance 8.3 23 23 100 none success 41
5 two-stage reimplantation MRSA CKD stage 3 7.7 13 13 100 none success 23
6 DAIR MRSA teicoplanin failure 10.6 11 21 52 AST elevation success 25
7 two-stage reimplantation MRCoNS intolerance 8.3 12 26 46 none success 27
8 two-stage reimplantation MRSA intolerance 7.2 18 49 37 none success 24
9 DAIR MRSA vancomycin MIC >1.5 mg/L 10 27 32 84 none success 26
10 two-stage reimplantation MRSA empirical 6.3 21 33 64 none failure 24
11 two-stage reimplantation MRCoNS intolerance 10 13 36 36 none success 34
12 two-stage reimplantation MRSA teicoplanin failure 6.7 14 39 36 none success 36
13 DAIR MRSA intolerance 7.4 14 20 70 none success 29
14 two-stage reimplantation MRCoNS empirical 8.3 16 22 73 none success 36
15 DAIR MRSA empirical 8.3 26 66 39 none failure 34
16 two-stage reimplantation MRCoNS empirical 10.6 11 19 58 none success 42
  1. DAP Daptomycin, MRSA Methicillin-resistant Staphylococcus aureus, MRCoNS Methicillin-resistant coagulase-negative staphylococci CKD, chronic kidney disease, MIC Minimum inhibitory concentration, AST Aspartate aminotransferase; intolerance, allergy to glycopeptide or phlebitis